# A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

> **NCT05225207** · — · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 658 (actual)

## Conditions studied

- Liver Neoplasms
- Carcinoma, Hepatocellular

## Interventions

- **OTHER:** Non-interventional

## Key facts

- **NCT ID:** NCT05225207
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225207, "A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05225207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*